2 days ago · Sage Therapeutics turns down Biogen's offer to buy the remaining stake in the company and is evaluating strategic alternatives to maximize shareholder value.

Jan 21, 2025 · Sage Therapeutics last week sued partner Biogen just days after receiving an unsolicited buyout offer from the pharma for nearly $470 million, according to reporting by Bloomberg Law. The suit, filed in a Delaware court, is sealed, according to Bloomberg, but in a separate court document, Sage noted ...

3 days ago · Following a lawsuit filed last week, Sage has officially rejected Biogen’s unsolicited buyout offer, which valued the embattled biotech at just $469 million.

3 days ago · (Reuters) -Sage Therapeutics said on Monday that its board has unanimously rejected Biogen’s $469 million offer, stating it "significantly undervalues" the company and does not serve ...

3 days ago · Sage Therapeutics has rejected the unsolicited acquisition offer it received earlier this month from longtime partner Biogen Inc.

3 days ago · Sage Therapeutics has rejected a buyout bid from partner Biogen and launched a review of strategic alternatives. Sage on Monday said its board determined that Biogen's $7.22-a-share proposal ...

2 days ago · Sage Therapeutics has rejected Biogen ’s $469m takeover offer, with its board of directors unanimously concluding that the bid “significantly undervalues” the company.

Sage and Biogen will continue to partner on ZURZUVAE® (zuranolone), the first and only FDA-approved oral treatment for women with postpartum depression (PPD) and will continue to work on their shared vision to help women suffering from PPD.

Jan 10, 2025 · Drugmaker Biogen will buy all outstanding shares of Sage Therapeutics that it does not already own for $7.22 apiece, a filing showed on Friday, sending the latter's stock up 34% in extended...

Jan 21, 2025 · Sage said it's board is reviewing Biogen's buyout offer, but a Mizuho analyst said a deal seems unlikely at the current price.